BioCardia Advances CardiAMP Cell Therapy Toward Japanese Approval

Event summary

  • PMDA determined clinical safety and efficacy evidence for CardiAMP Cell Therapy in ischemic heart failure is likely sufficient for market clearance in Japan.
  • FDA expressed no concerns on safety and agreed the benefits for patients who received therapy in the CardiAMP HF Trial were intriguing.
  • BioCardia received a preliminary Advisory Record from PMDA in line with expectations and is advancing towards Shonin submission for Pre-Market Approval (PMA) in Japan.
  • Primary results of the CardiAMP autologous cell therapy in chronic myocardial ischemia with refractory angina (BCDA-02) have been accepted for oral presentation at Euro PCR.
  • BioCardia ended Q1 2026 with $951,000 in cash and cash equivalents, down from $2,496,000 at the end of 2025.

The big picture

BioCardia's progress with CardiAMP Cell Therapy represents a significant step toward addressing a critical unmet need in the treatment of ischemic heart failure. The company's strategic focus on securing regulatory approvals in both Japan and the U.S. underscores the global potential of its cellular therapeutics. However, the financial constraints highlighted in the Q1 2026 results pose a challenge that could impact the company's ability to capitalize on these regulatory milestones.

What we're watching

Regulatory Pathway
The pace at which BioCardia can navigate the Shonin submission process and secure Pre-Market Approval (PMA) in Japan will determine the timeline for commercializing CardiAMP Cell Therapy in a market with an estimated 20,000 patients annually.
Clinical Trial Progress
The ongoing CardiAMP HF II trial is critical for securing FDA's Premarket Approval (PMA), and its progress will be a key indicator of BioCardia's ability to meet regulatory requirements.
Financial Sustainability
With cash reserves dwindling, BioCardia's ability to secure additional funding or achieve cost efficiencies will be crucial for sustaining operations and advancing its therapeutic candidates.

Related topics

Regulatory Approval Biotechnology Clinical Trial